RTTNews BiotechCodex · 实盘不做把握 6/10
北京时间·🕒 发布 19:21:27时区推断·⟳ 抓取 19:30:32·⚡ 决策 07-29 19:32:35 +2m03s·90.5 天前
MannKind的吸入型尼达尼布IPF 1b期安全性读数正面但仍属早期验证
INFLO-1仅为27名IPF患者、7天给药的1b期安全性/耐受性读数，未给出疗效终点，难以形成短线业绩重估。
📄 原文RTTNews Biotech↗ 原文
MannKind's Nintedanib DPI Shows Favorable Safety In IPF Patients
MannKind Corporation (MNKD) announced positive topline results from its Phase 1b INFLO-1 study of nintedanib dry powder…
不做 MannKind（MNKD.US）
不做：1b期小样本安全性读数方向正面但无疗效、无近期收入，且公司已提前预告三季度读数和Phase 2推进，开盘追多edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司此前已公告INFLO-1完成随机化、INFLO-2启动并预计2026年三季度披露INFLO-1数据，研发进度已进入市场日历。
- RTTNews报道INFLO-1达到主要安全性和耐受性目标，未见严重不良事件、胃肠道副作用、支气管痉挛或停药。市场反应:报道正文称MNKD盘前约3.94美元、上涨0.77%，反应温和。
- 2026-07-29 11:31 UTC市场反应Futu非一手行情工具返回MNKD最新价3.91美元、较前收跌1.01%，未确认出现足以证明重定价的强盘前反应。市场反应:MNKD.US 3.91美元，20日跌7.78%。
关键理由
- INFLO-1仅为27名IPF患者、7天给药的1b期安全性/耐受性读数，未给出疗效终点，难以形成短线业绩重估。
- 公司6月已公告INFLO-1读数将在2026年三季度披露且INFLO-2已推进，本次属于预期内早期读数兑现。
- MNKD一季度收入约9020万美元、市值约12.1亿美元，MNKD-201仍处Phase 2前后且商业化需多年，当前新增现金流为零。
主要风险
- 若公司后续在会议披露FVC等初步疗效信号，事件性质会从安全性进展升级为疗效验证，需要重新评估。
- 盘前媒体稿显示仅小幅上涨，若开盘被低流通生物科技资金快速拉升，追高容易变成早期临床读数的见光死交易。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 none
内部KB未命中本次MNKD-201读数的有效研报或纪要，仅返回其他公司临床进展，未提供可上调商业化价值的增量证据。
检索:MannKind nintedanib DPI INFLO-1 IPF phase 1b safety tolerability - 做多前查反向 · 来源 web · 日期 2026-03-23 · 影响 weakens
Avalyn AP02同为吸入型尼达尼布并已启动IPF二期，削弱MNKD-201早期安全性读数的稀缺性。
检索:MannKind nintedanib DPI competitor Avalyn AP02 inhaled nintedanib IPF 原文 ↗
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,010 字
MannKind Corporation (MNKD) announced positive topline results from its Phase 1b INFLO-1 study of nintedanib dry powder inhalation (DPI) in idiopathic pulmonary fibrosis (IPF), meeting its primary objective of demonstrating safety and tolerability.
The randomized, double-blind, placebo-controlled trial enrolled 27 patients across 10 U.S. sites and tested two multiple-ascending dose regimens over seven days. Results showed no serious adverse events, no gastrointestinal side effects, no bronchospasm, and no treatment discontinuations. Spirometry parameters were comparable between nintedanib DPI and placebo. Most patients experienced no cough, and when cough occurred, it was mild, transient, and resolved without intervention.
Chief Executive Officer Michael Castagna highlighted that across Phase 1a and 1b studies, more than 700 inhalations have been administered, including nearly 450 in IPF patients, with cough not posing a meaningful barrier to treatment.
The Phase 1a program in healthy volunteers has previously established a favorable safety profile, with rapid absorption and dose-proportional plasma concentrations consistent with deep-lung delivery.
MannKind is now advancing to its global Phase 2 INFLO-2 trial, which is actively enrolling patients. Additional data from INFLO-1 will be presented at a future conference.
MNKD has traded between $2.23 and $6.51 over the past year. The stock closed Tuesday's trading at $3.91, down 1.01%. In pre-market trading the stock is trading at $3.94, up 0.77%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 25, 2026 02:46 ET The latest policy decision from the European Central Bank dominated the scene this week that was relatively slow for economics news flow. In the U.S., main highlights were the weekly initial jobless claims and new home sales data. In Europe, the ECB rate decision and the latest inflation figures from the U.K. drew attention. In Asia, results of a private sector survey from India were in focus.
The randomized, double-blind, placebo-controlled trial enrolled 27 patients across 10 U.S. sites and tested two multiple-ascending dose regimens over seven days. Results showed no serious adverse events, no gastrointestinal side effects, no bronchospasm, and no treatment discontinuations. Spirometry parameters were comparable between nintedanib DPI and placebo. Most patients experienced no cough, and when cough occurred, it was mild, transient, and resolved without intervention.
Chief Executive Officer Michael Castagna highlighted that across Phase 1a and 1b studies, more than 700 inhalations have been administered, including nearly 450 in IPF patients, with cough not posing a meaningful barrier to treatment.
The Phase 1a program in healthy volunteers has previously established a favorable safety profile, with rapid absorption and dose-proportional plasma concentrations consistent with deep-lung delivery.
MannKind is now advancing to its global Phase 2 INFLO-2 trial, which is actively enrolling patients. Additional data from INFLO-1 will be presented at a future conference.
MNKD has traded between $2.23 and $6.51 over the past year. The stock closed Tuesday's trading at $3.91, down 1.01%. In pre-market trading the stock is trading at $3.94, up 0.77%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 25, 2026 02:46 ET The latest policy decision from the European Central Bank dominated the scene this week that was relatively slow for economics news flow. In the U.S., main highlights were the weekly initial jobless claims and new home sales data. In Europe, the ECB rate decision and the latest inflation figures from the U.K. drew attention. In Asia, results of a private sector survey from India were in focus.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。